Amyln announced that Ginger Graham, who was on its board of directors for seven years, will become the new CEO of the company. Amylin has a strong connection with Lilly; most of its upper management has been with Lilly at some point or the other for a long time. Ginger Graham is no exception. Ginger started with her career Lilly, and rose through the ranks in variety of functions to become the President of one of its subsidiaries, which eventually became Guidant. Recently, Ginger had been managing the strategy at Guidant, and was perhaps not very happy with her role. In April she chose to leave Guidant to pursue other interests.

Appointment of Ginger bodes well for the relationship Amylin is forging with Lilly for its Excendin-4 compound. Ginger Graham, having managed Sales and Marketing operation in US and abroad for Guidant, brings top quality management experience as the company gets ready for the launch of Symlin.